Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab Rollover Safety Study in MDS/CMML-2 (China cohort)
CTR20234098Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sabatolimab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Novartis. Started Dec 2023; status: completed.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on CTR20234098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234098.